| Authors: |
Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Verschraegen C; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States., Sigal D; Scripps Clinic and Scripps Cancer Center, La Jolla, CA, United States., Lenz HJ; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States., Hochster H; Rutgers Cancer Institute, New Brunswick, NJ, United States., Baysal MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chakraborty A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lee I; OBI Pharma USA, Inc., San Diego, CA, United States., Ristoski K; OBI Pharma USA, Inc., San Diego, CA, United States., Xu D; OBI Pharma USA, Inc., San Diego, CA, United States. |
